Journal of International Psychiatry

[Abstract] Objective To explore the clinical efficacy of agomelatine in the treatment of hypertension combined with depression. Methods Eighty-four patients with hypertension and depression were included from January 2020 - December 2023 were selected, and they were randomly divided into two groups using the coin toss method. All patients underwent antihypertensive treatment, with a control group of 41 cases treated with sertraline and an observation group of 43 cases treated with agomelatine. The Pittsburgh sleep quality index before and after treatment, PSQI）、 The Hamilton Depression Scale 17, HAMD-17) and coefficient of variation of blood pressure were compared. The Treatment Emergency Symptom Scale at 4 and 8 weeks of treatment, TESS) were compared. Results PSQI index of two groups of patients after treatment The HAMD-17 score significantly decreased compared to before treatment, but the PSQI index in the observation group was lower than that in the control group after treatment (P<0.05). After treatment, the coefficient of variation of blood pressure in both groups of patients significantly decreased, but the coefficient of variation of blood pressure in the observation group was lower than that in the control group (P<0.05). At 4 and 8 weeks of treatment, the TESS score in the observation group was lower than that in the control group (P<0.05). Conclusion Agomelatine in the treatment of hypertension with depression is equivalent to sertraline in improving depressive mood, but the former can improve sleep quality, stabilize arterial blood pressure, and have milder adverse reactions.

Key words Agomelatine; Sertraline; Hypertension Combined with Depression; Sleep Quality; Arterial Blood Pressure